Shanghai Henlius Biotech, Inc.





Delayed Hong Kong S.E. 04:08:35 2024-05-22 EDT 5-day change 1st Jan Change
18.84 HKD +4.67% Intraday chart for Shanghai Henlius Biotech, Inc. -.--% +35.54%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation MT
Henlius' EU Marketing Application for Denosumab Biosimilar Accepted and Validated by Regulator MT
Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications for Hlx14 CI
Shanghai Henlius Biotech, Inc. Announces Marketing Authorization Applications for Biosimilar of Denosumab HLX14 (Recombinant Anti-Rankl Human Monoclonal Antibody Injection) Validated by the European Medicines Agency CI
Henlius Biotech Gets China Approval for New Indications of Arthritis Drug MT
Henlius Biotech Amends License Deals with Palleon for Bifunctional Protein Products MT
National Medical Products Administration Approves Shanghai Henlius Biotech, Inc.'S the Supplemental Applications of Handayuan (Adalimumab Injection) for the New Indications CI
US FDA Grants Investigational New Drug Clearance for Alligator Bioscience's Late-stage Gastric Cancer Treatment Trial MT
Shanghai Henlius Biotech, Inc. Announces Amendments to the Collaboration and License Agreement with Palleon for Tumour-Related Target-Sialidase Bifunctional Fusion Protein CI
Shanghai Henlius Biotech, Inc. Receives Investigational New Drug Clearance from the US Food and Drug Administration to Initiate Hlx22 in 1st Line HER2+ Gastric Cancer Patients CI
Shanghai Henlius Biotech Gets Go-Ahead for Clinical Trials of Breast Cancer Drug in China MT
Shanghai Henlius Biotech, Inc. Announces Approval of Application for Clinical Trials of HLX78 (lasofoxifene) by the National Medical Products Administration CI
Henlius Biotech Gets US FDA Clearance for Phase 3 Trial of Gastric Cancer Combination Therapy MT
Shanghai Henlius Biotech, Inc. Announces Application for the Phase 3 Clinical Trial of HLX22 in Combination with Trastuzumab and Chemotherapy as the First-Line Treatment of HER2 Positive Advanced Gastric Cancer Approved by the United States Food and Drug Administration CI
Henlius Biotech Logs 1.35 Billion Yuan Revenue in Q1 MT
Shanghai Henlius Biotech's Cancer Drug Gets the Nod from US FDA MT
Shanghai Henlius Biotech Doses 1st Patient in Fibrosis Drug Clinical Study in China MT
Shanghai Henlius Biotech, Inc. Announces First Subject Dosed in Phase 1 Clinical Study in Healthy Subjects of HLX6018 in Mainland China CI
Henlius Biotech Gets Clearance for China Clinical Trial of Carcinoma Drug MT
Shanghai Henlius Biotech, Inc. Announces Application for the Clinical Trial of HLX53 (Anti-TIGIT Fc Fusion Protein) in Combination with HANSIZHUANG (Serplulimab Injection) and HANBEITAI (Bevacizumab Injection) for the First-Line Treatment of Local Advanced or Metastatic Hepatocellular Carcinoma was Approved by the National Medical Products Administration CI
Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint MT
Shanghai Henlius Biotech, Inc Announces Phase 3 Comparative Clinical Study of Prolia® and Xgeva® Biosimilar Candidate HLX14 Met Primary Endpoints CI
Phase 3 Trial of Shanghai Henlius Biotech’s Osteoporosis Drug Meets Primary Study Endpoints MT
Shanghai Henlius Biotech, Inc. Announces International Multi-Centre Phase 3 Clinical Study of Biosimilar of Denosumab HLX14 for Treatment of Osteoporosis in Postmenopausal Women at High Risk for Fracture has Met Primary Study Endpoints CI
Shanghai Henlius Biotech Turns to Profit in 2023 MT
Chart Shanghai Henlius Biotech, Inc.
More charts
Shanghai Henlius Biotech Inc. is a China-based company principally involved in the research, development, production and sales of monoclonal antibody products. The Company’s main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The Company is also engaged in the provision of related technical services. The Company operates its businesses primarily in Mainland China and the United States.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
17.47 CNY
Average target price
16.7 CNY
Spread / Average Target

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 2696 Stock
  4. News Shanghai Henlius Biotech, Inc.
  5. Henlius Biotech Terminates License Agreement for Chiome Bioscience's Tumor Drug